🇺🇸 FDA
Pipeline program

Alirocumab

Pro00114645

Phase 2 small_molecule on_hold

Quick answer

Alirocumab for Non Small Cell Lung Cancer is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Non Small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
on_hold

Clinical trials